You just read:

Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)

News provided by

Immune Pharmaceuticals Inc.

Jun 20, 2017, 09:14 ET